This research investigates how HIV disrupts the developing immune system in early life. Using a baby monkey model of HIV infection, the study identifies immune signals that either promote or limit infection spread. The findings could guide new immune-targeted therapies that improve survival and long-term outcomes for children living with HIV.

This research shows that the sympathetic nervous system is disrupted at the earliest stages of ALS, despite sympathetic neurons themselves remaining intact. Early loss of signalling receptors may contribute to muscle degeneration and disease progression, identifying new opportunities for earlier diagnosis and therapies that preserve muscle function and improve patient outcomes.

This research develops patient-specific digital twins of the heart to improve radiofrequency ablation for cardiac arrhythmias. By simulating heat transfer, tissue damage, and electrical activity, these computational models could improve treatment accuracy, reduce repeat procedures, accelerate medical device development, and advance the future of personalised cardiovascular medicine.

This research reveals how Streptococcus evades immune attack by shedding its hair-like surface proteins, distracting immune cells while provoking excessive immune activation. The findings provide a new explanation for how recurrent strep infections can trigger autoimmune diseases and suggest treatments should target both the bacteria and the immune response.

This research develops a targeted anti-VEGF therapy for wet age-related macular degeneration that can be injected under the skin rather than directly into the eye. In animal studies, the drug successfully reached the eye and reduced abnormal blood vessel growth, offering a safer, cheaper, and more convenient treatment for preventing blindness.

This research investigates a new targeted treatment strategy for kidney cancer by inhibiting the cancer-promoting protein PIM1 while enhancing TRAIL-mediated apoptosis. Together with the FDA-approved drug ONC201, this combination restores cancer cells' ability to self-destruct, offering a promising therapeutic approach now being evaluated in preclinical studies.

This research develops hybrid lipo-polymeric nanoparticles that overcome major limitations of current mRNA vaccine technology. The particles can be freeze-dried, rapidly loaded with mRNA, and simultaneously deliver therapeutic drugs. Their flexibility improves vaccine storage and distribution while enabling powerful combination therapies, including enhanced cancer treatments with improved survival in preclinical models.

This research investigates how aging changes blood stem cells, causing them to produce excess sticky platelets that increase the risk of heart attack and stroke. By identifying the genetic mechanisms behind this age-related shortcut, the work aims to develop therapies that reduce cardiovascular disease while improving healing in patients with low platelet counts.

This research develops orally administered nanoparticle therapies for metronomic chemotherapy in ovarian cancer. By delivering smaller drug doses directly to tumours over extended periods, it aims to reduce side effects, overcome drug resistance, improve patient quality of life, and make long-term cancer treatment easier and more effective.

This research investigates whether the diabetes drug dapagliflozin (DAPA) can be repurposed to treat metabolic dysfunction-associated steatotic liver disease (MASLD). Using laboratory models, it examines fat accumulation and NHE1 ion channel function, aiming to develop a cost-effective treatment for two closely linked metabolic diseases with one existing medicine.